Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
486
Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published about 1 year ago
- Discuss
To determine whether recommended amounts of leisure-time physical activity (ie, 7.5-15 metabolic equivalent task [MET] hours/week) are associated with lower cancer risk, describe the shape of the dose-response relationship, and explore associations with moderate- and vigorous-intensity physical activity.
260
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published almost 5 years ago
- Discuss
Patients with cancer are more likely to file for bankruptcy than the general population, but the impact of severe financial distress on health outcomes among patients with cancer is not known.
183
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published about 5 years ago
- Discuss
The use of biopsy-derived pharmacodynamic biomarkers is increasing in early-phase clinical trials. It remains unknown whether drug development is accelerated or enhanced by their use. We examined the impact of biopsy-derived pharmacodynamic biomarkers on subsequent drug development through a comprehensive analysis of phase I oncology studies from 2003 to 2010 and subsequent publications citing the original trials.
167
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published over 4 years ago
- Discuss
We determined the utility of the 21-Gene Recurrence Score (RS) in predicting late (> 5 years) distant recurrence (LDR) in stage I and II breast cancer within high and low-ESR1-expressing groups.
162
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published almost 5 years ago
- Discuss
The objective of this study was to determine whether the 21-gene Recurrence Score (RS) provides clinically meaningful information in patients with de novo stage IV breast cancer enrolled in the Translational Breast Cancer Research Consortium (TBCRC) 013.
158
Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published over 4 years ago
- Discuss
Accurate illness understanding enables patients to make informed decisions. Evidence of the influence of prognostic discussions on the accuracy of illness understanding by patients would demonstrate the value of discussions.
126
Androgen Deprivation Therapy and Future Alzheimer’s Disease Risk
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published about 5 years ago
- Discuss
To test the association of androgen deprivation therapy (ADT) in the treatment of prostate cancer with subsequent Alzheimer’s disease risk.
93
American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published almost 5 years ago
- Discuss
American Society of Clinical Oncology (ASCO), the leading medical professional oncology society, is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention. As the main providers of cancer care worldwide, our patients, their families, and our communities look to us for guidance regarding all things cancer related, including cancer prevention. Through this statement and accompanying recommendations, ASCO hopes to increase awareness of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the discussion of HPV vaccination on its likely ability to prevent millions of cancer deaths, and increase HPV vaccination uptake via greater involvement of oncology professionals in ensuring accurate public discourse about HPV vaccination and calling for the implementation of concrete strategies to address barriers to vaccine access and acceptance.
89
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published about 3 years ago
- Discuss
Alcohol drinking is an established risk factor for several malignancies, and it is a potentially modifiable risk factor for cancer. The Cancer Prevention Committee of the American Society of Clinical Oncology (ASCO) believes that a proactive stance by the Society to minimize excessive exposure to alcohol has important implications for cancer prevention. In addition, the role of alcohol drinking on outcomes in patients with cancer is in its formative stages, and ASCO can play a key role by generating a research agenda. Also, ASCO could provide needed leadership in the cancer community on this issue. In the issuance of this statement, ASCO joins a growing number of international organizations by establishing a platform to support effective public health strategies in this area. The goals of this statement are to: • Promote public education about the risks between alcohol abuse and certain types of cancer; • Support policy efforts to reduce the risk of cancer through evidence-based strategies that prevent excessive use of alcohol; • Provide education to oncology providers about the influence of excessive alcohol use and cancer risks and treatment complications, including clarification of conflicting evidence; and • Identify areas of needed research regarding the relationship between alcohol use and cancer risk and outcomes.
88
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
- OPEN
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published 5 months ago
- Discuss
To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC).